EastPharma Ltd. reported audited consolidated earnings results for the full year ended December 31, 2012. For the year, the company reported revenue of $231,983,492 compared to revenue of $242,263,513 for the same period a year ago. Profit before tax was $16,348,563 compared to loss before tax of $16,531,771 last year.

Net profit was $11,599,029 compared to net loss of $18,059,267 last year. Net profit attributable to equity holders of the parent was $9,075,962 or $0.13 per basic and diluted share compared to net loss attributable to equity holders of the parent of $15,676,055 or $0.23 per basic and diluted share last year. Net cash provided by operating activities was $14,488,426 compared to $7,393,375 last year.

Purchases of property, plant and equipment was $27,597,410 compared to $23,122,201 last year. The company's sales decrease was mainly due to the strengthening of the USD against the Turkish Lira. EBITDA in 2012 was $48.4 million compared to $30.3 million in 2011 representing an EBITDA margin of 21.0% compared to 12.5% in 2011.

After adjustment for these extraordinary items EBITDA was $16.2 million, which corresponds to an adjusted EBITDA margin of 6.7% in 2011.